The Long Run with Luke Timmerman Ep175: Andy Scharenberg on in vivo CAR-T cell therapies
Mar 16, 2025
Andy Scharenberg, Co-founder and CEO of Umoja Biopharma, is advancing in vivo CAR-T cell therapies to make life-saving treatments more accessible. He talks about the challenges and breakthroughs in CAR T-cell treatments, including the transformative possibilities of gene therapies. Scharenberg reflects on his journey from medicine to molecular innovation and highlights the importance of collaboration in tackling complex immune disorders. He also shares exciting developments aimed at revolutionizing cancer treatment and enhancing patient outcomes.
AI Snips
Chapters
Transcript
Episode notes
Family of Education
- Andy Scharenberg's family valued education.
- His parents were a physics professor and a mathematician, influencing his interest in science.
Path to Pediatrics and Immunology
- Scharenberg chose pediatrics because of the direct impact on people's lives.
- His interest shifted from neuroscience to immunology due to the latter's more tractable problems at the time.
Arrival at Seattle Children's
- Scharenberg joined Seattle Children's Hospital in 2000.
- He collaborated with Hans Ochs on inherited immune diseases and explored gene therapy.